Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVT-01 in moderate persistent atopic asthma (Phase 2)
2006-004190-94Phase 2Completed
- Sponsor
- Avontec
- Start
- Oct 2006
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing AVT-01 10 mg once daily with Placebo (2 arms). Primary endpoint: PC20 doubling concentration difference. Started Oct 2006; status: completed.
02
Drugs
AVT-01
03
Conditions
asthma
Beyond the preview
Go deeper on 2006-004190-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004190-94.